A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1626-1631

  Cunningham, C Casey ^a,b   Holmlund, Jon T ^c   Schiller, Joan H ^d   Geary, Richard S ^c   Kwoh, T Jesse ^c   Dorr, Andrew ^c   Nemunaitis, John ^a,b  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c ISIS PHARMACEUTICALS   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CGP 69846A;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ALANINE TRANSAMINASE; ANOREXIA; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; FEVER; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-RAF; THIONUCLEOTIDES; TREATMENT OUTCOME; VOMITING;

EID: 0034026007     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Orr, R. M., and Monia, B. P. Antisense therapy for cancer. Curr. Res. Mol. Ther., 1: 102-108, 1998.
2. Agrawal, S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol., 14: 376-387, 1996.
3. Marais, R., Light, Y., Paterson, H. F., Mason, C. S., and Marshall, C. J. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J. Biol. Chem., 272: 4378-4383, 1997.
4. Crews, C. M., Alessandrini, A., and Erikson, R. L. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science (Washington DC), 258: 478-480, 1992.
5. Skolnik, E. Y., Batzer, A., Li, N., Lee, C. H., Lowenstein, E., Mohammadi, M., Margolis, B., and Schlessinger, J. The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science (Washington DC), 260: 1953-1955, 1993.
6. Wang, H. G., Rapp, U. R., and Reed, J. C. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell, 87: 629-638, 1996.
7. Storm, S. M., and Rapp, U. R. Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol. Lett., 67: 201-210, 1993.
8. Daum, G., Eisenmann-Tappe, I., Fries, H. W., Troppmair, J., and Rapp, U. R. The ins and outs of Raf kinases. Trends Biochem. Sci., 19: 474-480, 1994.
9. Webb, C. P., Van Aelst, L., Wigler, M. H., and Van de Woude, G. F. Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc. Natl. Acad. Sci. USA, 95: 8773-8778, 1998.
10. Brennscheidt, U., Riedel, D., Kolch, W., Bonifer, R., Brach, M. A., Ahlers, A., Mertelsmann, R. H., and Herrmann, F. Raf-1 is a necessary component of the mitogenic response of the human megakaryoblastic leukemia cell line MO7 to human stem cell factor, granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 9. Cell Growth Differ., 5: 367-372, 1994.
11. Zhou, J. N., Ljungdahl, S., Shoshan, M. C., Swedenborg, J., and Linder, S. Activation of tissue-factor gene expression in breast carcinoma cells by stimulation of the RAF-ERK signaling pathway. Mol. Carcinog., 21: 234-243, 1998.
12. Investigator's Brochure ISIS 5132 (CGP 69846A). Isis Pharmaceuticals, Inc., 1998.
13. Monia, B. P., Johnston, J. F., Geiger, T., Muller, M., and Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med., 2: 668-675, 1996.
14. Geary, R. S., Leeds, J. M., Henry, S. P., Monteith, D. K., and Levin, A. A. Antisense oligonucleotide inhibitors for the treatment of cancer. I. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des., 12: 383-393, 1997.
15. Levin, A. A., Monteith, D. K., Leeds, J. M., Nicklin, P. L., Geary, R. S., Butler, M., Templin, M. V., and Henry, S. P. Toxicity of oligonucleotide therapeutic agents. In: S. T. Crooke (ed.), Handbook of Experimental Pharmacology, Vol. 131, pp. 169-215. Berlin: Springer-Verlag, 1998.
16. Galbraith, W. M., Hobson, W. C., Giclas, P. C., Schechter, P. J., and Agrawal, S. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev., 4: 201-206, 1994.
17. Yacyshyn, B. R., Bowen-Yacyshyn, M. B., Jewell, L., Tami, J. A., Bennett, C. F., Kisner, D. L., and Shanahan, W. R., Jr. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology, 114: 1133-1142, 1998.
18. Stevenson, J. P., Yao, K-S., Gallagher, M., Friedland, D., Mitchell, E. P., Cassella, A., Monia, B., Kwoh, J., Yu, R., Holmlund, J., Dorr, F. A., and O'Dwyer, P. J. Phase I clinical/pharmacokinetic, and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J. Clin. Oncol., 17: 2227, 1999.
19. Srinivasan, S. K., and Iversen, P. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J. Clin. Lab. Anal., 9: 129-137, 1995.
20. Gardner, W. D., Haselby, J. A., and Hoch, S. O. Identification of a major serum DNA-binding protein as factor B of the alternative complement pathway. J. Immunol., 124: 2800-2806, 1980.
21. Henry, S. P., Giclas, P. C., Leeds, J., Pangburn, M., Auletta, C., Levin, A. A., and Kornbrust, D. J. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J. Pharmacol. Exp. Ther., 281: 810-816, 1997.
22. Sheehan, J. P., and Lan, H. C. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood, 92: 1617-1625, 1998.
23. Leeds, J. M., Graham, M. J., Truong, L., and Cummins, L. L. Quantitation of phosphorothioate oligonucleotides in human plasma. Anal. Biochem., 235: 36-43, 1996.
24. Muszynski, K. W., Ruscetti, F. W., Heidecker, G., Rapp, U., Troppmair, J., Gooya, J. M., and Keller, J. R. Raf-1 protein is required for growth factor-induced proliferation of hematopoietic cells. J. Exp. Med., 181: 2189-2199, 1995.
25. Sarmiento, U. M., Perez, J. R., Becker, J. M., and Narayanan, R. In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res. Dev., 4: 99-107, 1994.
26. Bridgewater, J. A., Nelstrop, A. E., Rustin, G. J., Gore, M. E., McGuire, W. P., and Hoskins, W. J. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J. Clin. Oncol., 17: 501-508, 1999.
27. O'Dwyer, P. J., Stevenson, J. P., Gallagher, M., Cassella, A., Vasilevskaya, I., Monia, B. P., Holmlund, J., Dorr, F. A., and Yao, K. S. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin. Cancer Res., 5: 3977-3982, 1999.
28. Riva, C., Lavieille, J. P., Reyt, E., Brambilla, E., Lunardi, J., and Brambilla, C. Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance. Eur. J. Cancer B Oral Oncol., 31B: 384-391, 1995.
29. Rasouli-Nia, A., Liu, D., Perdue, S., and Britten, R. A. High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity. Clin. Cancer Res., 4: 1111-1116, 1998.
30. Britten, R. A., Perdue, S., Opoku, J., and Craighead, P. Paclitaxel is preferentially cytotoxic to human cervical tumor cells with low Raf-1 kinase activity: implications for paclitaxel-based chemoradiation regimens. Radiother. Oncol., 48: 329-334, 1998.
31. Warenius, H. M., Seabra, L. A., and Maw, P. Sensitivity to cis-diamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not c-raf-1 protein. Int. J. Cancer, 67: 224-231, 1996.
32. Gokhale, P. C., McRae, D., Monia, B. P., Bagg, A., Rahman, A., Dritschilo, A., and Kasid, U. Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense Nucleic Acid Drug Dev., 9: 191-201, 1999.
33. Kasid, U., Pfeifer, A., Brennan, T., Beckett, M., Weichselbaum, R. R., Dritschilo, A., and Mark, G. E. Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science (Washington DC), 243: 1354-1356, 1989.
34. Holmlund, J. T., Monia, B. P., Kwoh, T. J., and Dorr, F. A. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development. Curr. Opin. Mol. Ther., 1: 372-385, 1999.